Amgen: Aimovig Launch Looks Strong, Monitor Biosimilar Developments

- Initial data points on prescription trends for Aimovig suggest a strong launch for the drug and for the anti-CGRP class.

- Amgen faces upcoming biosimilar competition for Neulasta, but also expects its own portfolio of biosimilars to continue to develop. This includes Amgen's Humira biosimilar, which will launch soon in the EU.

- Amgen recently filed an sNDA for a once-weekly Kyprolis dose in combination with dexamethasone. The drug continues to track towards a $1-2 billion drug by 2022.

Read More